7 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 35363301 | Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. | 2022 Jun 1 | 1 |
2 | 34439125 | ELOVL5-Mediated Long Chain Fatty Acid Elongation Contributes to Enzalutamide Resistance of Prostate Cancer. | 2021 Aug 5 | 1 |
3 | 31967357 | Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation. | 2020 Apr | 3 |
4 | 32042320 | Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts. | 2020 | 2 |
5 | 32205016 | A phase I dose-escalation study of enzalutamide in combination with theĀ AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. | 2020 May | 1 |
6 | 29220539 | Significance and mechanism of androgen receptor overexpression and androgen receptor/mechanistic target of rapamycin cross-talk in hepatocellular carcinoma. | 2018 Jun | 1 |
7 | 26712685 | Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer. | 2016 Jun 1 | 1 |